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Abstract 
We used immunohistochemistry and flow cytometry to assess apoptosis in human 
glioblastoma multiforme (GBM). Our immunohistochemical study revealed 
apoptosis of glioma cells expressing glial fibrillary acidic protein and of CD3+ T cells 
infiltrating GBM. To quantify and phenotype the apoptotic T cells, we performed 
flow cytometry on lymphocytes separated from GBM. The cells were stained with 
annexin-V-FLUOS/propidium iodide to identify apoptosis. We found that high 
proportions of both the CD4+ and CD8+ T cells were apoptotic. In particular, we 
found that T cells expressing Fas ligand (Fas-L, CD95L) were eight times more 
vulnerable to apoptosis than those not expressing Fas-L, which suggests that the T-
cell apoptosis is induced by overactivation of the T-cell receptor, possibly in the 
absence of appropriate costimulation. Our results have implications for the design of 
immunotherapies for GBM.  
Keywords: Glioblastoma; T cell; apoptosis; tumour; Fas (CD95)  
1. Introduction 
Apoptosis is a form of controlled cell death that occurs under numerous physiological and 
pathological conditions, including in glioblastoma multiforme (GBM) (Kuriyama et al., 2002 
and Schiffer et al., 1995). It is generally assumed that the apoptotic cells within GBM are 
tumour cells themselves. Indeed, the rate of apoptosis has been linked to prognosis by some 
authors (Kuriyama et al., 2002 and Nakamizo et al., 2002). However, the presence of 
apoptotic cells within GBM may be more complex than previously assumed since recent 
evidence has suggested that the T lymphocytes infiltrating GBM may also undergo apoptosis 
(Didenko et al., 2002). 
Glioma patients are known to have a depressed immune system (Dix et al., 1999). The nature 
of this immunodeficiency is complex and incompletely understood, but apoptosis of tumour-
infiltrating lymphocytes may be a significant factor. In this study we used 
immunohistochemistry to identify apoptosis in both tumour cells and T cells, and performed 
flow cytometry of separated lymphocytes to quantify and phenotype apoptotic T cells in 
GBM. Our immunohistochemical studies demonstrated apoptosis of T cells and glioma cells, 
and flow cytometry revealed a high frequency of apoptosis in both CD4+ and CD8+ T cells 
infiltrating GBM, particularly in T cells expressing Fas ligand (CD95 ligand; Fas-L). Our 
results are likely to have implications for the design of vaccine therapies for GBM. 
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2. Methods 
2.1. Tumour specimens 
Tumour specimens were handled routinely for histological analysis and graded by a 
neuropathologist according to the WHO system (Kleihues et al., 1993). Fifteen specimens that 
were identified as glioblastoma multiforme (WHO grade IV, GBM) were used in this study. 
Freshly resected samples of these tumours were taken directly from the operating room for 
processing, that included cell separation and flow cytometry analysis. 
2.2. Examination of semithin sections 
Three of the 9 tumours used for immunohistochemistry (see below) were also examined using 
semithin sections. Small fragments of tumour (2–4 mm diameter) were fixed in 
glutaraldehyde. Subsequently they were embedded in epoxy resin and 1–2 µm sections were 
cut. Sections were mounted on glass slides, stained with methylene blue and examined at high 
power with a light microscope. 
2.3. TUNEL analysis, immunohistochemistry and dual labelling 
Nine tumours were analyzed by immunohistochemistry. Tumour specimens were cut into 
small blocks and fixed in formalin, then embedded in paraffin. Six micrometer-thick sections 
were deparaffinized with xylene, rehydrated in graded concentrations of alcohol, and washed 
in water. Antigen retrieval was performed by microwaving at medium power in 0.01 M 
sodium citrate (pH 6). Non-specific labelling was inhibited by incubating the slides with a 
blocking solution (Tris-HCl, 0.1 M, pH 7.5 containing 3% bovine serum albumin (BSA) and 
20% normal bovine serum) for 30 min at room temperature. 
To analyze tissue sections for apoptosis, the TUNEL method was used. Although TUNEL can 
label necrotic cells as well as apoptotic cells (Gold et al., 1994), this problem is easily 
overcome by assessing the distribution of positive TUNEL cells and correlating the slides 
with sections stained with haematoxylin and eosin (H and E). We used a commercially 
available TUNEL-staining kit (Roche Applied Sciences) and followed the manufacturer's 
instructions, including the use of positive and negative controls. 
Subsequent to TUNEL staining, sections were immunostained with astrocyte-specific or T-
cell-specific antibodies. Labelling using primary antibodies (anti-GFAP and anti-CD3, mouse 
anti-human, 1:50, BD Biosciences) occurred at 4 °C overnight. After washing the slides 
several times with phosphate-buffered saline, a secondary antibody was applied (biotinylated 
goat anti-mouse, 1:500, BD Biosciences) at room temperature for 1 h. The signal was 
visualized using streptavidin-Texas Red conjugates (1:500, Roche Applied Sciences; 30 min 
at room temperature). Negative control experiments in which no primary antibody was added, 
were performed in each batch of staining experiments. Autofluorescence was quenched by 
treating the slides with Sudan Black B (0.3% in 70% ethanol) for 5 min at room temperature 
before TUNEL staining and after immunolabelling. 
Slides were visualized using alternate filters on a fluorescent microscope, and images were 
recorded using a digital camera. Corresponding images were subsequently fused using Adobe 
Photoshop® computer software. Given the potential inaccuracies, we made no attempts to 
quantify the degree of apoptosis using immunohistochemistry. 
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2.4. Magnetic separation of T cells and analysis of apoptosis by 
flow cytometry 
Fresh tumour tissue was taken from the operating room in Hartmann's solution. The tumour 
was immediately cut into small pieces in cell culture medium (RPMI/5% FCS). Cells were 
then passed through a cotton wool filter to remove debris, and counted using a 
haemocytometer before magnetic separation and flow cytometry. Enzymatic digestion was 
not used. Six tumours were analyzed in this way. A further 3 tumours, because of a greater 
availability of tissue, underwent isotype-control analysis before and after cell separation (see 
below). 
Some of each specimen was kept for analysis of the whole tumour. The remainder was used 
for magnetic separation of CD3+, CD4+ and CD8+ cells using the manufacturer's instructions 
(Miltenyi Biotec). In brief, cells were resuspended in 90 µl of buffer (phosphate-buffered 
saline (PBS) with 0.5% BSA and 2 mM EDTA, pH 7.2) to which 10 µl of the primary 
antibody (anti-CD3, anti-CD4 or anti-CD8, mouse anti-human, BD Biosciences) was added. 
The cells were then incubated at 4°C for 10 min, washed with buffer, centrifuged and then 
resuspended in 80 µl of buffer. Twenty microlitres of magnetic-bead labelled secondary 
antibody (goat-antimouse IgG microbeads, Miltenyi Biotec) were then added and the cells 
were then incubated at 4 °C for 15 min. Subsequently, the cells were washed in buffer and 
passed through a magnetic column according to the manufacturer's instructions. Negative and 
positive cells were collected. 
After separation of CD3+, CD4+ and CD8+ cells, specimens were analyzed for apoptosis using 
annexin-V-FLUOS/propidium iodide labelling and flow cytometry using a commercially 
available kit. In brief, cells were centrifuged and labelled with a mixture of annexin-V 
conjugated with fluorescein, and propidium iodide according to the manufacturer's 
instructions (Roche Applied Science). Cells were analyzed by flow cytometry, and viable 
cells (annexin-V negative, propidium iodide negative), cells in early apoptosis (annexin-V 
positive, propidium iodide negative), and cells in late apoptosis or necrosis (annexin-V 
positive, propidium iodide positive) were identified and counted. A minimum of 5000 cells 
were counted for each sample. 
2.5. Isotype-control experiments 
In order to establish that cells positively selected by magnetic separation were specifically 
labelled by anti-CD3 antibody and not non-specifically labelled, isotype controls were 
performed before and after separation in 3 tumours. Single-cell suspensions were divided into 
2 aliquots (approximately 1 × 107 cells each) – one was labelled with CD3-APC (Becton 
Dickinson, mouse IgG1 anti-human) and the other with an isotype-control antibody linked to 
APC (Becton Dickinson, mouse IgG1). Labelling was carried out as described above for 
magnetic separation. After keeping some specimen aside from each aliquot, the labelled cells 
were then passed through a magnetic column as described above. Positive cells were collected 
and, alongside the pre-separation specimen from the same aliquot, were analyzed by flow 
cytometry. 
2.6. Four-colour flow cytometry 
Three specimens were used for this analysis. Single-cell suspensions were prepared as 
described above, and then passed through a Ficoll gradient. Cells were then taken from the 
interface and washed twice with cold PBS. Approximately 1 × 107 cells were then 
resuspended in cold PBS-azide. To this were added propidium iodide (5 µl, 10 µg/ml), 
annexin-V PE (BD Pharmingen) (5 µl), anti-CD3-APC (20 µl, BD-Pharmingen) and anti-Fas-
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L-FITC (1 µl, Bender MedSystems). The cells were then incubated on ice in the dark for 
60 min, centrifuged and washed with cold PBS-azide. Flow cytometry was then performed. 
Concurrently, isotype-control antibodies were used to control for non-specific binding. 
Results were compared to peripheral blood mononuclear cells from control subjects so that 
lymphocytes could be identified by forward- and side-scatter characteristics. 
3. Results 
3.1. Semithin sections, immunohistochemistry and TUNEL analysis 
When semithin sections were examined with high power, apoptotic bodies showing 
characteristic nuclear fragmentation could readily be identified (Fig. 1a). However, it was not 
possible, on morphological criteria alone, to identify the cellular origin of these apoptotic 
cells.  
 
Fig. 1. A GBM is analyzed for the presence of apoptosis using semithin sections and dual labelling 
immunohistochemistry. a. Semithin section of a GBM illustrating apoptosis with characteristic nuclear 
fragmentation (short arrow) as well as a mitotic figure (long arrow). The cell of origin of the apoptotic 
figure is not able to be determined. b–d. Dual labelling immunohistochemistry using anti-GFAP 
antibody and TUNEL staining. b. Staining with anti-GFAP and visualized with Texas Red. Tumour 
cells are shown to be GFAP+. c. TUNEL staining of the same slide. Apoptotic bodies are identified by 
bright green staining. d. When the anti-GFAP and TUNEL images are combined, TUNEL positivity 
can be seen in GFAP+ tumour cells (red + green = yellow, bottom centre), as well as in GFAP− cells 
(green). 
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Using fluorescent immunohistochemistry, GFAP+ and CD3+ cells could be readily identified 
within GBM (Fig. 1 and Fig. 2). As is widely recognized, the degree of GFAP positivity was 
variable, and not all tumour cells were positive using fluorescent immunolabelling. All 
specimens analyzed showed at least some GFAP reactivity. CD3+ cells were observed in 6 out 
of the 9 specimens analyzed. These cells were seen scattered throughout the parenchyma of 
GBM, either as single cells or in small groups, as well as around blood vessels. Overall, CD3+ 
T cells represented only a few percent of the total number of cells. 
 
Fig. 2. Dual labelling immunohistochemistry of a GBM using anti-CD3 antibody and TUNEL staining. 
a. GBM stained with H and E showing a region of endothelial proliferation. b. Immunolabeling with 
anti-CD3 antibody and Texas Red shows a group of CD3+ cells within this region (red). c. TUNEL 
staining of the same slide. Several apoptotic cells are seen (bright green). d. When the images are 
combined, some of the apoptotic cells are shown to be CD3+, i.e. tumour-infiltrating T lymphocytes 
(yellow). 
Using TUNEL analysis, positive cells were seen in all specimens. Areas of necrosis could 
easily be identified when correlated with H and E slides. Apoptotic cells were identified if the 
TUNEL+ cell was not within an area of necrosis. In addition, these cells tended to have small, 
condensed nuclei, a morphological characteristic of apoptosis. 
In dual labelling using anti-GFAP as the primary antibody, TUNEL+ cells were seen in 
GFAP+ (i.e. tumour cells) and GFAP− cells (Fig. 1). TUNEL+/GFAP− cells were seen both in 
isolation and adjacent to GFAP+ cells. Similarly, when using anti-CD3 as the primary 
antibody, TUNEL+ cells were seen in CD3+ and CD3− cells (Fig. 2). Most TUNEL+ cells did 
not stain for CD3. TUNEL+/CD3+ cells (i.e. apoptotic T cells) occurred as isolated, 
intraparenchymal cells as well as in small groups (Fig. 2). 
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3.2. Single-cell separation, annexin-V/propidium iodide labelling 
and flow cytometry 
Three tumours were analyzed for CD3 staining using APC-labelled anti-CD3 and anti-isotype 
antibodies, before and after magnetic separation using anti-CD3 as the primary antibody. The 
results showed that cells positively selected for CD3 expression by magnetic separation did 
show some increase in non-specific antibody binding. However, using magnetic separation, 
CD3+ cells could be readily concentrated to a high degree. On average, before magnetic 
separation, CD3+ cells represented only 1–2% of the cell population; after magnetic 
separation, CD3+ cells represented almost 70% of the positively selected cell population (Fig. 
3). Nonspecific binding could account for only a minority of this.  
 
Fig. 3. Flow cytometry detecting APC labelling. A minimum of 10,000 cells were counted in each 
case. a. Cells were labelled with CD3-APC then passed through a magnetic column. Pre-separation 
cells (whole) (black) are compared to positive cells (grey). The significant concentration of CD3+ cells 
by magnetic separation is demonstrated. b. Cells were labelled with isotype-APC and passed through a 
magnetic column. Positive cells do show a small amount of concentration using this method, consistent 
with some non-specific labelling. 
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Six GBM underwent analysis of CD3+ cells, and 3 of these underwent analysis of CD4+ and 
CD8+ cells. In general, CD3+ cells represented less than 2% of the total number of cells within 
any given tumour specimen (data not shown). In tumours that were separated according to 
CD3, CD4 or CD8 expression, the proportions of cells that were viable, were undergoing 
early apoptosis and those undergoing late apoptosis or necrosis were analyzed. In tumours 
that were separated according to annexin-V expression, the proportions of CD3+ cells were 
analyzed in the annexin-V positive and negative fractions. 
Using annexin-V/propidium iodide labelling, cells separated on the basis of CD3, CD4 or 
CD8 positivity showed a consistent decrease in the proportion of viable cells, and an increase 
in the proportion of cells in early apoptosis and late apoptosis/necrosis (Table 1 and Table 2; 
Fig. 4 and Fig. 5). For example, when the results of the 6 GBM examined were combined, 
there was a significant difference in the mean proportions of cells in early apoptosis between 
CD3+ and CD3− fractions (22.6% vs. 6.8%, p < 0.01). There was also an increased mean 
proportion of cells in late apoptosis/necrosis in CD3+ fractions, compared to CD3− cells 
(33.0% vs 4.6%, p < 0.01). Because late apoptosis and necrosis can not be differentiated using 
this method, we believe the figure for early apoptosis is more significant. Similar results were 
obtained when CD4+ and CD8+ fractions were compared to CD4− and CD8− fractions, 
respectively (Table 2, Fig. 5). Although the combined results of the 3 tumours examined did 
not show a statistically significant difference between the means of positive and negative 
fractions, in each individual example there was a consistent increase in the amount of 
apoptosis in positive fractions compared to negative cell fractions (CD4: early apoptosis, 
mean increase = 3.5-fold, SD 0.47; CD8: early apoptosis, mean increase = 3.8-fold, SD 1.3).  
Table 1. Summary of results from 6 GBM  
Mean (%) CD3− CD3+ p-value 
Viable cells 88.2 43.4 < 0.01 
Early apoptosis 6.8 22.6 < 0.01 
Late apoptosis/necrosis 4.6 33.0 < 0.01 
Cells were separated by magnetic labelling and then stained with annexin-V-FLUOS/propidium iodide. 
Flow cytometry was then performed (see Fig. 3). The results in the table represent the mean 
percentages from our studies on 6 GBM. A minimum of 5000 cells were counted for each tumour, 
either as viable (annexin-V negative and propidium iodide negative), undergoing early apoptosis 
(annexin-V positive and propidium iodide negative) or undergoing late apoptosis or necrosis (annexin-
V positive and propidium iodide positive). P-values are for Student's t-test (unpaired, 2-tailed). 
3.3. Analysis of four-colour flow cytometry 
Three GBM were analyzed in this fashion. By comparing tumour-infiltrating lymphocytes to 
peripheral blood mononuclear cells, lymphocytes could be identified on the basis of forward- 
and side-scatter characteristics. Lymphocytes were then further analyzed. Cells that stained 
with propidium iodide (i.e. necrosis or late apoptosis) were excluded from further analysis. 
The remaining cells were examined on the basis of CD3-APC, Fas-L-FITC and Annexin V-
PE staining. Of cells that were CD3+, 27% were Annexin-V PE+ (range 21–35%). Of CD3+ 
cells, 59% were Fas-L+ (range 55–65%), and 41% were Fas-L−. For CD3+ Fas-L+ cells, 41% 
were Annexin V-PE+ (range 36–49%), compared to 5% that were CD3+ Fas-L− (range 4–7%) 
(Fig. 6). This indicates that expression of Fas-L increases the susceptibility of T cells to 
apoptosis by a factor of 8.  
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4. Discussion 
In this study we have analyzed T-lymphocyte apoptosis within GBM by 
immunohistochemistry and flow cytometry of separated lymphocytes. Our 
immunohistochemical studies revealed apoptosis of both T cells and glioma cells in GBM. 
Flow cytometry demonstrated that high proportions of CD4+ T cells and CD8+ T cells were 
apoptotic and that T cells expressing Fas-L were much more likely to undergo apoptosis than 
those not expressing Fas-L. 
Table 2.  Summary of results from 3 GBM that were analyzed for apoptosis 
after separation of CD4+ cells and CD8+ cells  
 
Mean (%) CD4− CD4+ p-value CD8− CD8+ p-value p-value CD4+ vs CD8+ 
Viable 90.1 44.7 0.15 90.8 44.2 0.18 0.98 
Early apoptosis 7.12 25.6 0.19 6.4 23.3 0.18 0.87 
Late apoptosis 2.8 29.7 0.12 2.8 32.5 0.19 0.88 
Figures represent the mean percentages of a minimum of 5000 cells counted. P-values for Student's t-
test (unpaired, 2 tailed) are given. 
The presence of apoptosis within high-grade glial tumours has been well recognized 
(Kuriyama et al., 2002 and Schiffer et al., 1995). Our study using dual-labelling 
immunohistochemistry has shown that apoptosis does occur in GFAP-positive tumour cells, a 
fact that, as far as we can determine, has not been previously been shown using this 
methodology. Two recent papers have found a positive association between apoptotic index 
and survival (Kuriyama et al., 2002 and Nakamizo et al., 2002). Earlier studies also showed 
an improved survival with increased apoptosis (Korshunov et al., 1999 and Rhodes, 1998) 
although others have not found such a relationship (Heesters et al., 1999 and Nakamura et al., 
1997). This inconsistency of results may be related to the variable identity of apoptotic cells, 
which has not been widely recognized. The common assumption has been that apoptotic 
bodies represent tumour cells, yet within GBM there exists a heterogeneous cell population 
that includes tumour cells, endothelial cells, leukocytes and normal brain cells. Apoptosis 
could potentially occur in any of these cell populations. 
Significant lymphocytic infiltrates have been previously observed in between 11% and 58% 
of high-grade gliomas (Bertrand and Mannen, 1960, Palma et al., 1978, Ridley and Cavanagh, 
1971 and Schiffer et al., 1974). Some authors also observed that patients with more prominent 
lymphocytic infiltrates had a better survival (Brooks et al., 1978 and Palma et al., 1978). 
Using cell separation and flow cytometry, we identified CD3+ T cells in all tumours 
examined, but by immunohistochemistry observed CD3+ cells in only 6 of 9 GBM, a figure in 
keeping with previous histological studies (Bertrand and Mannen, 1960 and von Hanwehr et 
al., 1984). Flow cytometry is likely therefore to be more sensitive and thus has a significant 
advantage when examining the T-cell phenotype. It is worth noting, however, that since T 
cells represent only a small fraction of the total cell population within a GBM, the 
contribution of apoptotic T cells to the total number of apoptotic cells is likely to be small. 
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Fig. 4. Flow cytometry after Annexin-V FLUOS/propidium iodide (PI) staining. The bottom left 
quadrant (both annexin-V and propidium iodide negative) are viable cells. Annexin-V positive and 
propidium iodide negative cells (bottom right quadrant) are early apoptotic cells. Late 
apoptosis/necrosis is represented in the top right quadrant (both annexin-V and propidium iodide 
positive). a. Analysis of a single-cell suspension prepared from a GBM (T50) shows less than 1% of 
cells in early apoptosis. b. Analysis of the same tumour after magnetic cell separation (see Materials 
and methods for details). The CD3− fraction also shows less than 1% of cells in early apoptosis. c. 
CD3+ cells (i.e. tumour-infiltrating T lymphocytes) in this same tumour showed 23% of cells were in 
early apoptosis. 
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Fig. 5. Flow cytometry after Annexin-V FLUOS/propidium iodide (PI) staining. This GBM (T71) was 
analyzed after separation of CD3+ cells, CD4+ cells and CD8+ cells. CD3− cells showed a lower rate of 
early apoptosis (a, 9.7%) compared to CD3+ cells (b, 17.4%), CD4+ cells (c, 22.9%) and CD8+ cells (d, 
18%). 
It is clear that effective anti-tumour cell-mediated immune responses are not generated in 
patients with glioma. It has long been recognized that patients harbouring malignant gliomas 
exhibit depressed cellular immune responses compared to healthy individuals (Mahaley et al., 
1983 and Young et al., 1976). Although gliomas express tumour-associated antigens (Parney 
et al., 2000), their ability to present these antigens to T cells is controversial. This may relate 
to their major histocompatibility complex (MHC) expression. Because gliomas are likely to 
express only low levels of class I MHC molecules (Miyagi et al., 1990 and Saito et al., 1988), 
CD8+ cytotoxic T cells may be relatively ineffective in eliminating glioma cells. Class II 
molecules are generally expressed by professional antigen-presenting cells (Ni and O'Neill, 
1997). Within the CNS, microglia are the usual class II MHC-positive cells (Gehrmann et al., 
1995 and Theele and Streit, 1993). Microglia and macrophages are present in increased 
numbers within human gliomas in situ (Leung et al., 1997, Roggendorf et al., 1996 and Rossi 
et al., 1987). However, the absence of antiglioma immunity suggests that these microglia are 
not functioning as effective immunostimulating cells. Indeed it is possible that they may be 
subverted by the tumour into secreting factors that support glioma growth (Mantovani et al., 
1992). Although transforming growth factor-β (TGF-β) produced by gliomas has been 
suggested to have a T-cell immunosuppressant role, the concentration of TGF-β in culture 
supernatants obtained from tumours does not correlate with the concentrations of TGF-β 
required to inhibit T-cell function in vitro (Dix et al., 1999). 
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Fig. 6. Four-colour flow cytometry of tumour-infiltrating lymphocytes after excluding propidium 
iodide positive (PI+) cells and analyzing only CD3+ cells. The graph represents Annexin V-PE+ cells vs 
FasL+ cells. This demonstrates that the proportion of FasL+ T cells that are apoptotic is much greater 
than the percentage of FasL− T cells that are apoptotic. 
Although gliomas are infiltrated by lymphocytes to varying degrees, it has been reported that 
glioma-infiltrating lymphocytes are inactivated (Black et al., 1992). Using flow cytometry, we 
have shown that less than half of the T cells infiltrating GBM are viable, and that an average 
of 22.6% are in early apoptosis. Didenko et al. (2002) demonstrated apoptosis of T cells 
infiltrating GBM by immunohistochemistry using caspase-3 as a marker of apoptosis and 
anti-CD3 for labelling T cells. They estimated that 10% of T cells infiltrating GBM were 
apoptotic. T-cell subsets were not examined in their study. Our immunohistochemical study 
using TUNEL staining demonstrated apoptosis of T cells and glioma cells in GBM. Our use 
of lymphocyte separation and flow cytometry yielded a more accurate estimate of the 
frequency of T-cell apoptosis. We found that high proportions of both CD4+ T cells and CD8+ 
T cells are apoptotic. Our flow cytometry data on magnetically separated T cells was 
supported by our data from four-colour flow cytometry; there was a reasonable concordance 
between the two methods in estimating the percentage of apoptotic T cells. Apoptosis of 
tumour-infiltrating lymphocytes has also been demonstrated in other tumours, including 
melanoma, colon cancer and hepatocellular carcinoma (Hahne et al., 1996, O'Connell et al., 
1996 and Strand et al., 1996). 
T-cell apoptosis has been identified as a critical process in recovery from immune-mediated 
CNS damage (Pender et al., 1992, Tabi et al., 1994 and Pender and Rist, 2001). Apoptotic T 
cells in the CNS are phagocytosed by macrophages, microglia, astrocytes and 
oligodendrocytes (Nguyen and Pender, 1998 and Magnus et al., 2002). It has been proposed 
that activation-induced apoptosis of previously activated autoreactive T cells in the target 
organ is a major mechanism for maintaining tolerance (Pender, 1999). Activation-induced 
apoptosis (i.e. apoptosis of T cells triggered by activation of the T-cell receptor) is mediated 
through the Fas (CD95) pathway. Activation of T lymphocytes increases their expression of 
Fas and induces their expression of Fas-L within 24 h, and they become susceptible to Fas-
mediated apoptosis 3–4 days after activation (Brunner et al., 1995, Ju et al., 1995 and Dhein 
et al., 1995). The ligation of Fas on the surface of the T cell can be mediated by Fas-L on the 
same T cell or by Fas-L expressed by other cells (Brunner et al., 1995 and Dhein et al., 1995). 
Using four-colour flow cytometry on lymphocytes extracted from GBM, we have shown that 
T cells expressing Fas-L are 8 times more likely to undergo apoptosis than those not 
expressing Fas-L. Although we did not measure Fas expression on apoptotic T cells, Fas is 
known to be expressed on apoptotic T cells in GBM (Didenko et al., 2002). Our finding that T 
Journal of Neuroimmunology (2006) 175 (1-2):  59-68.                   doi:10.1016/j.jneuroim.2006.03.006     
 
cells expressing Fas-L are much more likely to undergo apoptosis than T cells not expressing 
Fas-L is similar to what occurs in the CNS during spontaneous recovery from experimental 
autoimmune encephalomyelitis (White et al., 1998) and suggests that T-cell apoptosis in 
GBM is activation-induced and is occurring via the ligation of Fas by Fas-L on the same T 
cell. Apoptosis of T cells within GBM may explain, to a significant extent, the ineffectiveness 
of cell-mediated immunity towards gliomas. 
Didenko et al. (2002) demonstrated apoptotic T cells adjacent to Fas-L-expressing glioma 
cells and concluded that Fas-L expression by glioma cells activates the Fas pathway in 
infiltrating T cells and leads to T-cell apoptosis as a tumour defence mechanism. It seems 
unlikely that glioma-cell Fas-L expression is the dominant mechanism leading to T-cell 
apoptosis because Fas-L expression by glioma cells is by no means universal, either within 
individual tumours or amongst GBM as a group (Husain et al., 1998 and Saas et al., 1997). 
An alternative role for glioma cells in inducing T-cell apoptosis is that glioma cells act as 
non-professional antigen-presenting cells which present tumour antigens to T cells but do not 
provide a co-stimulatory signal. Co-stimulation by professional antigen-presenting cells 
inhibits apoptosis in previously activated T cells (Groux et al., 1993 and Liu and Janeway, 
1990). Therefore we suggest that apoptotic deletion of T cells in GBM is due to activation-
induced apoptosis following antigen presentation by glioma cells and microglia. This 
mechanism is similar to that which has been suggested to account for apoptosis of 
autoreactive T cells in the CNS during spontaneous recovery from experimental autoimmune 
encephalomyelitis, where astrocytes and microglia may act as non-professional antigen-
presenting cells (Pender, 1999 and Pender and Rist, 2001). Our hypothesis that T-cell 
apoptosis in GBM results from overstimulation of the T-cell receptor in the absence of 
appropriate costimulation is consistent with the findings of Prins et al. (2001) who showed 
that tumour-infiltrating lymphocytes functioned poorly when tested in vitro, with decreased 
proliferative activity and other characteristics of defective T cells. These phenotypic changes 
mirrored changes seen in normal CD8+ T cells cultured with polyclonal mitogens for an 
extended period. Prins et al. (2001) concluded that T cells were undergoing apoptosis due to 
over-activation related to the glioma microenvironment and that the T cells were thus not 
contributing to anti-tumour immunity. Our findings are also consistent with those of Chahlavi 
et al. (2005) who, using an in vitro glioblastoma model, found that activated T cells are more 
sensitive to apoptosis than resting T cells and also provided evidence that Fas-L expression by 
glioma cells is not a major mechanism for T-cell apoptosis. 
In conclusion, we have demonstrated apoptosis in high proportions of the CD4+ and CD8+ T 
lymphocytes infiltrating GBM. Our finding that T cells expressing Fas-L are much more 
likely to undergo apoptosis than those not expressing Fas-L indicates that the T-cell apoptosis 
is activation-induced. We suggest that T-cell apoptosis in GBM results from overstimulation 
of the T cell receptor in the absence of appropriate co-stimulation. The results have 
implications for the immunotherapy of GBM because they suggest that, without appropriate 
co-stimulation in the CNS, T cells are unlikely to mount an effective anti-GBM attack.  
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